HYDERABAD: Pharma major Dr Reddy’s Laboratories on Saturday said its active pharmaceutical ingredients manufacturing facility at Middleburgh in New York has been issued a Form 483 with two observations by the US drug regulator, US Food and Drug Administration (US FDA).
“We have been issued a Form 483 with two observations, which we will address within the stipulated timeline,” Dr Reddy’s said in a regulatory filing .
The Hyderabad-based company said the good manufacturing practices (GMP) inspection was conducted by US FDA between May 12, 2025, and May 16, 2025, the company said.
A Form 483 is issued by USFDA inspectors to the management of the company at the end of an onsite inspection if inspectors find any violations of the Food, Drug and Cosmetic (FD&C) Act or other regulations, as per USFDA.
“We have been issued a Form 483 with two observations, which we will address within the stipulated timeline,” Dr Reddy’s said in a regulatory filing .
The Hyderabad-based company said the good manufacturing practices (GMP) inspection was conducted by US FDA between May 12, 2025, and May 16, 2025, the company said.
A Form 483 is issued by USFDA inspectors to the management of the company at the end of an onsite inspection if inspectors find any violations of the Food, Drug and Cosmetic (FD&C) Act or other regulations, as per USFDA.
You may also like
No probe against Kerala MLA who 'freed' man from forest dept custody: Minister
HM Amit Shah hails Operation Sindoor as a turning point in India's security doctrine
RCB move to top, KKR eliminated as rain ruins IPL comeback in Bengaluru
IPL 2025: KKR Knocked Out As Rain Washes Off RCB Clash
Fred and Rose West's child's chilling joke about their sister that helped expose murders
